两年的临床study outcomes for the Defocus Incorporated Multiple Segments (DIMS) spectacle lens

This study reports two year results from a randomized clinical trial examining Defocus Incorporated Multiple Segments (DIMS) spectacle lenses for myopia control. The findings showed around 50% refractive and 60% axial length efficacy in Hong Kong Chinese children, with an absolute effect of 0.44D lower refraction and 0.34mm less axial elongation in DIMS wearers.

一年的近视控制奇观镜片的近视效果

这项研究报告了一年的持续随机临床试验,该试验检查了具有高度非球形透镜(HAL)或略微非球形透镜(SAL)技术的眼镜镜头。研究结果表明,HAL镜头在前12个月中控制了60-70%的折射率和轴向进展,SAL为30-40%。

Influence of orthok treatment zone diameter and pupil diameter on myopia progression

This study evaluates how orthok treatment zone diameter influences change in refraction and axial eye length over 1-year in children previously fit with orthok lenses of varying back optic zone diameter, to reveal that where treatment zone diameter was less than pupil diameter orthok’s myopia control efficacy appeared to be improved.

MiSight’s Impact on Binocular and Accommodative Function

The purpose of this 2 year study was to determine the effect of MiSight contact lenses used to control myopia on binocular vision and accommodation in children, as compared with children wearing SV spectacles, with the researches finding no significant differences in binocular and accommodative measures between the study groups.

Determining the Optimal Concentration of Atropine

尽管用于近视管理多年,但在文献和临床验光实践中都存在有关阿托品最佳浓度的重大争议。灯灯研究通过研究了0.05%,0.025%和0.01%阿托品的疗效来阐明这一谜团,以减缓近视的进展。

近视的近视控制误解1天六年

In this review we explore the 6-year results for MiSight 1 day recently presented at the 2020 American Academy of Optometry meeting. Based on the abstract, children who were older at initial fitting (11-15 years) progressed similarly over 3 years to matched children who were treated for 6 years, indicating that older children could still gain a treatment effect from MiSight 1 day.

MiSight 3-Year Data Analysis

This 2019 study evaluated 3-year MiSight efficacy in a randomised clinical trial conducted across four different sites, in Singapore, Canada, Portugal and the UK to yield promising findings, with efficacy results comparable to previous studies, and overall high satisfaction reported by subjects. Eye Care Practitioners can utilise these results to confidently educate patients and their families on the efficacy of this treatment option.

Novel Contact Lens Design for Myopia Control

The authors conducted a 2-year double blinded, randomised control trial to evaluate the efficacy of novel contact lens designs for myopia control. Lens I and II induced myopic defocus across a large portion of the retina, while Lens III and IV featured an extended depth of focus incorporating higher order aberrations to modulate retinal image quality. This technology is utilised in the Mark’Ennovy Mylo the and Seed 1-Day Pure EDOF lens.

Posterior Scleral Reinforcement as a means of myopia control

Pathologic myopia is one of the major causes of blindness worldwide. Degenerative changes associated with high myopia, including posterior staphyloma formation and scleral thinning, are caused by the progressive elongation of globe axial length and stretching of the sclera, choroid and retina. The aim of this meta-analysis was to investigate and quantitatively define the efficacy of PSR in controlling axial elongation and refraction progression.

Baidu